Fujita 2014.
Study characteristics | ||
Methods | Randomized, double‐blind, placebo‐controlled, parallel group trial of oral sumatriptan | |
Participants | Participants from 17 centres in Japan were 10‐17 years of age, diagnosed with migraine with or without aura per ICHD‐2 criteria for a minimum of 6 months, and 2‐8 attacks monthly lasting for > 3 h in the last 2 months prior to entry. Randomized (N = 178); withdrawn (N = 34); intention‐to‐treat and primary efficacy analysis (N = 144) |
|
Interventions | Oral sumatriptan 25 mg (1 tablet and 1 matching placebo), sumatriptan 50 mg (2 tablets), or placebo (2 tablets) taken as soon as possible (within 30 minutes) after the development of a migraine with grade 3 or more pain | |
Outcomes |
Other reported outcomes:
|
|
Headache severity scale | 5‐grade scale | |
Funding source | GlaxoSmithKline | |
Publication | Journal and Clinical Trial Registry | |
Notes | — | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote: "Investigator (or subinvestigator) completed the registration form and sent it to the randomization center by facsimile. The randomization center. . . assigned a randomization number to the patient." |
Allocation concealment (selection bias) | Low risk | Quote: "For allocation of the participants, a computer‐generated list of random numbers was used." |
Blinding (performance bias and detection bias) All outcomes | Low risk | Quote: "The investigator (or subinvestigator) dispensed the investigational product to the patient according to the computer‐generated randomization number." |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Comment: used last observation carried forward (LOCF) |
Selective reporting (reporting bias) | Low risk | Comment: all stated outcomes were reported |